Newsroom

Scanning electron microscope image of Mycobacterium tuberculosis.

Interview

On the occasion of World Tuberculosis Day, Jennifer Herrmann, scientist in the department Microbial Natural Products at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), talks about the epidemiology of the disease and her current research into new active substances against the causative agent of tuberculosis.

23.04.2021

HIPS

News

After exposure to a virus through infection or vaccination, the body activates a number of cells and mechanisms that can provide targeted defense against the pathogen. For the global containment of the SARS-CoV-2 pandemic, the question of how long this protection lasts is an important factor. Prof Carlos Guzmán, vaccine researcher at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, summarizes what is known about long-term immunity to SARS-CoV-2 and what difference it makes whether immunity is acquired through vaccination or infection.

08.04.2021

HZI Campus

News

In May 2020, the international consortium iCAIR® started a research project aimed at developing therapeutics against SARS-CoV-2. The Helmholtz Centre for Infection Research (HZI), which joined forces with the consortium's core team last year, is also closely involved in this project. The HZI researchers under the leadership of Prof. Ulrich Kalinke have expanded the iCAIR® outstanding talent pool: they boast a successful track record in antiviral drug research, in particular against human pathogenic RNA viruses, and have compound libraries as well as test models and primary virus isolates. In addition, a team from Fraunhofer ITMP led by Prof. Carsten Claussen and Dr. Ole Pless is on board as a temporary project partner. The iCAIR® research team already can report promising results, which were presented by iCAIR® coordinator Prof. Armin Braun and others at Fraunhofer ITEM's virtual workshop "Models of Lung Disease" in January.

08.04.2021

TWINCORE

Rasterelektronenmikroskopische Aufnahme von Mycobacterium tuberculosis

News

Every year, about 10 million people become infected with tuberculosis and 1.4 million die from it. This makes tuberculosis not only one of the most widespread infectious diseases, but also the deadliest. Similar to malaria or HIV, the prevalence of tuberculosis is strongly dependent on social factors; it is considered a classic disease of the poor. In addition to a lack of medical care, other problems hinder the containment of tuberculosis, such as antibiotic resistance and undesirable drug-drug interactions.

24.03.2021

News

The bacterium Pseudomonas aeruginosa is among the most common causes of pneumonia and poses a major challenge to hospitals worldwide. The treatment of infections with Pseudomonas aeruginosa is usually challenging because the bacterium forms so-called biofilms, which protect it from drugs. Dr Martin Empting and his team, in collaboration with several groups at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), have now developed an innovative method to disrupt the formation of these biofilms and thus facilitate the treatment of infections with Pseudomonas aeruginosa. The researchers have published their findings in the journal Advanced Science.

19.03.2021

HZI Campus

HIPS

Grafik Myelom-Zellen mit BCMA-Expression

News

Therapeutically modified white blood cells hold great potential in the treatment of multiple myeloma, a malignant cancer of the bone marrow. However, they can lead to serious resistance in treated patients. In close cooperation, medical doctors and scientists from the University Hospital and the Helmholtz Institute for RNA-based Infection Research in Würzburg have now investigated the causes of this previously unexplained phenomenon. In the process, they uncovered a crucial resistance mechanism. The results were just published in the journal Nature Medicine.

11.03.2021

HIRI

Back to the first page
...
60
61
62
63
...
155

HZI in the media

... haben. Ein Forschungsteam des Helmholtz-Instituts für RNA-basierte Infektionsforschung (HIRI) in Würzburg hat in Zusammenarbeit ...

14.04.2026

PresseBox - DE

... der Infektion und Nozizeption“ am Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig. Nozizeption ist der Fachbegriff ...

14.04.2026

Verband Deutscher Biologen e.V.

... recht nicht bei Fabian Leendertz, der in Greifswald das „Helmholtz-Institut für One Health“ leitet. Im ...

14.04.2026

FAZ.NET

... sich auch das Helmholtz-Institut für Pharmazeutische Forschung Saarland ( HIPS ), das Helmholtz-Zentrum für Infektionsforschung ( HZI ) ...

09.04.2026

Deutsches Ärzteblatt

... ÖAW in Wien und nun Gruppenleiter am Helmholtz Zentrum für Infektionsforschung in Braunschweig, forscht an ...

08.04.2026

DerStandard.de

... group within the Microstar Program at the Helmholtz Centre for Infection Research (HZI) and a ...

31.03.2026

Informations Dienst Wissenschaft

... an der Medizinischen Hochschule Hannover und am Helmholtz Institut für Infektionen in Braunschweig die Wirkung ...

28.03.2026

Hamburger Abendblatt

led by wildlife veterinarian Fabian Leendertz, who heads the Helmholtz Institute for One Health, took hundreds of samples from meat and

27.03.2026

Science.org

Gesellschaft. Apropos Standort Braunschweig: Auch das Helmholtz-Zentrum für Infektionsforschung HZI, in dessen Räumlichkeiten auf dem ...

27.03.2026

transkript

Helmholtz Centre for Infection Research

After infection with SARS-CoV-2, up to 10 percent of people in Germany go on to develop Long COVID.

26.03.2026

Mirage.News

... von verschiedenen Hörnchen, wie jüngste Erkenntnisse des Helmholtz Instituts für One Health in Greifswald kürzlich ...

26.03.2026

Tagesschau

zur Bekämpfung der Tuberkulose und des Helmholtz-Zentrums für Infektionsforschung erstellt. Zahlreiche weitere Fachgesellschaften und

24.03.2026

Deutsches Ärzteblatt

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.